Glatopa

In 2015, the 20 mg/mL dose of the product was approved in the United States as the first generic version of the drug glatiramer acetate and was a fully substitutable generic that was approved for all indications of the dose.

Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.

Momenta Pharmaceuticals Inc . MNTA reported a loss per share of 63 cents in the quarter, wider than the year-ago loss of 46 cents.Revenues in the.

MADRID, 15 (EUROPA PRESS) La Agencia Americana del Medicamento (FDA, por sus siglas en inglés) ha aprobado el uso de acetato de glatiramero inyectable 40 mg/ml, registrado por Sandoz (división de Novartis) con el nombre de 'Glatopa', como una versión gené